Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid …
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that all 84 clinical sites in its pivotal Phase 3 study for early Alzheimer’s disease (AD) are now fully activated and …
Annovis Bio Reaches Key Milestone as Alzheimer’s Phase 3 Trial Gains Momentum Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has appointed Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer, bringing on a seasoned financial leader to guide the company through …
Annovis Bio Names Mark Guerin CFO as Buntanetap Nears Late-Stage Milestones Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug …
Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that Chief Executive Officer Maria Maccecchini, Ph.D., will deliver a presentation at the H.C. Wainwright 27th Annual Global Investment Conference in …
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual …
Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the successful transfer and rewrite of all its intellectual property protections to cover a newly developed crystalline form of its lead drug …
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap Read More